Abstract
A 3-month, open-label, single-center study was conducted to determine whether a uniquely formulated and physiologically balanced topical treatment serum containing multiple growth factors, cytokines, peptides, antioxidants and depigmenting agents could improve the visible signs of facial photodamage. Thirty-seven females, aged 32–55 years, with mild to severe, fine and coarse peri-ocular wrinkles were enrolled and completed the study. Subjects applied the treatment serum to the face twice daily for 3 months in conjunction with a basic skincare regimen. Clinical evaluations of photodamage were performed at baseline and months 1, 2 and 3. Cutometer measurements and subject self-assessment questionnaires were also conducted during the study. Clinical evaluations showed statistically significant reductions in fine wrinkles and coarse wrinkles and improvements in skin texture, tone and radiance starting at month 1 with continued improvements at months 2 and 3. Cutometer readings showed decreased skin extensibility and increased resiliency. Subject self-assessments confirmed that the beneficial effects of the treatment serum were readily observed by the users. The treatment serum was well-tolerated with no treatment-related adverse events reported during the 3-month study. Use of this novel treatment serum produced significant improvements in the visible signs of facial photodamage.
Acknowledgements
Financial support of this study was provided by Skin-Medica, Inc.
Declaration of interest: Dr Atkin, Dr Trookman and Dr Rizer are investigators for SkinMedica, Inc. Mr Gotz is a consultant for SkinMedica, Inc. Ms Schreck, Ms Ho, Ms Ford and Dr Mehta are all employees of SkinMedica, Inc. The authors alone are responsible for the content and writing of this paper.